32 research outputs found
Appalachian Transition: A cross sector approach to regional transition.
Appalachia is made up of many mountains, many communities and many different sectors of work. The Appalachian Transition Fellows based out of the Highlander Education Center have spent 9 months working throughout central Appalachia to build cross sector bridges and to help further a positive growth in the region’s economy. Through the fellowship people are working with different models of transition, including value chains, worker owner cooperatives, local food initiatives, policy making, etc. In this session we will be breaking out into different groups each led by one or two fellows to talk about various ways these different models could be beneficial in different communities in Appalachia. There is value in working not only across county and state lines, but also working across economic sector boundaries. This is a workshop to understand the different models being used and to further discuss how to growth between these models for a more diverse and stronger Appalachian economy
Recommended from our members
Direct oxide reduction demonstration, small-scale studies
This project was initiated to provide process design information to the Plutonium Recovery Project (PRP). Although direct oxide reduction (DOR) has been operated in a production mode both at the Rocky Flats Plant (now operated by EG&G, Inc.) and Los Alamos National Laboratory, many aspects of the process are ill-defined. Because the PRP plans include significant DOR capability, a well-defined process should minimize capital cost and maximize productivity. Reduced radiation exposure may also be realized. A detailed, statistically valid investigation of the direct oxide reduction process was carried out utilizing 100 grams or less of plutonium dioxide per experiment. Conditions were established for obtaining 95% + yields. Conclusions drawn from the results of the experimental work were utilized to make recommendations for future large-scale investigative and confirmative work as well large-scale production demonstration work. 4 refs., 5 figs., 14 tabs
Understanding attitudes toward adolescent vaccination and the decision-making dynamic among adolescents, parents and providers
Cost effectiveness analysis of Year 2 of an elementary school-located influenza vaccination program–Results from a randomized controlled trial
BACKGROUND: School-located vaccination against influenza (SLV-I) has the potential to improve current suboptimal influenza immunization coverage for U.S. school-aged children. However, little is known about SLV-I’s cost-effectiveness. The objective of this study is to establish the cost-effectiveness of SLV-I based on a two-year community-based randomized controlled trial (Year 1: 2009–2010 vaccination season, an unusual H1N1 pandemic influenza season, and Year 2: 2010–2011, a more typical influenza season). METHODS: We performed a cost-effectiveness analysis on a two-year randomized controlled trial of a Western New York SLV-I program. SLV-I clinics were offered in 21 intervention elementary schools (Year 1 n = 9,027; Year 2 n = 9,145 children) with standard-of-care (no SLV-I) in control schools (Year 1 n = 4,534 (10 schools); Year 2 n = 4,796 children (11 schools)). We estimated the cost-per-vaccinated child, by dividing the incremental cost of the intervention by the incremental effectiveness (i.e., the number of additionally vaccinated students in intervention schools compared to control schools). RESULTS: In Years 1 and 2, respectively, the effectiveness measure (proportion of children vaccinated) was 11.2 and 12.0 percentage points higher in intervention (40.7 % and 40.4 %) than control schools. In year 2, the cost-per-vaccinated child excluding vaccine purchase () consisted of three component costs: (A) the school costs (32.33); and (C) the vendor costs excluding vaccine purchase (59.73 (Year 1) and 39.54). However, taking indirect costs (e.g., averted parental costs to visit medical practices) into account, vaccination was less costly in SLV-I (24.07 in Year 2) than in medical practices. CONCLUSIONS: Our two-year trial’s findings reinforced the evidence to support SLV-I as a potentially favorable system to increase childhood influenza vaccination rates in a cost-efficient way. Increased efficiencies in SLV-I are needed for a sustainable and scalable SLV-I program
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Abstract
BACKGROUND:
The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
METHODS:
We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy.
RESULTS:
In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups.
CONCLUSIONS:
Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)
Recommended from our members
Direct oxide reduction demonstration, small-scale studies
This project was initiated to provide process design information to the Plutonium Recovery Project (PRP). Although direct oxide reduction (DOR) has been operated in a production mode both at the Rocky Flats Plant (now operated by EG G, Inc.) and Los Alamos National Laboratory, many aspects of the process are ill-defined. Because the PRP plans include significant DOR capability, a well-defined process should minimize capital cost and maximize productivity. Reduced radiation exposure may also be realized. A detailed, statistically valid investigation of the direct oxide reduction process was carried out utilizing 100 grams or less of plutonium dioxide per experiment. Conditions were established for obtaining 95% + yields. Conclusions drawn from the results of the experimental work were utilized to make recommendations for future large-scale investigative and confirmative work as well large-scale production demonstration work. 4 refs., 5 figs., 14 tabs
Recommended from our members
Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates
Although autodialer centralized reminder and recall (C-R/R) from state immunization information systems (IISs) has been shown to raise childhood vaccination rates, its impact on human papillomavirus (HPV) vaccination rates is unclear. In a 4-arm pragmatic randomized controlled trial across 2 states, we randomly selected practices representative of the specialty (pediatrics, family medicine, and health center) where children received care. Within each practice, patients 11 to 17.9 years old who had not completed their HPV vaccine series (NY: N = 30 616 in 123 practices; CO: N = 31 502 in 80 practices) were randomly assigned to receive 0, 1, 2, or 3 IIS C-R/R autodialer messages per vaccine dose. We assessed HPV vaccine receipt via the IIS, calculated intervention costs, and compared HPV vaccine series initiation and completion rates across study arms. In New York, HPV vaccine initiation rates ranged from 37.0% to 37.4%, and completion rates were between 29.1% and 30.1%, with no significant differences across study arms. In Colorado, HPV vaccine initiation rates ranged from 31.2% to 33.5% and were slightly higher for 1 reminder compared with none, but vaccine completion rates, ranging from 27.0% to 27.8%, were similar. On adjusted analyses in Colorado, vaccine initiation rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.07 and 1.04, respectively); completion rates were slightly higher for 1 and 3 C-R/R messages (adjusted risk ratios 1.02 and 1.03, respectively). IIS-based C-R/R for HPV vaccination did not improve HPV vaccination rates in New York and increased vaccination rates slightly in Colorado